Share your thoughts and take our survey on non-needle epinephrine devices. Hot off the press – read our Fall 2025 federal budget submission, get the latest updates on the National School Food Program, explore a newly published article supporting our foodservice initiative, Think Food Allergy, and check out a research article that speaks to how our AllergyAware.ca online training program boosts anaphylaxis preparedness for school staff. Plus get the latest updates in sublingual epinephrine film.
Advocacy in action: Share your thoughts on non-needle epinephrine devices
Epinephrine is first line treatment for a severe allergic reaction (anaphylaxis) and in Canada, we currently use epinephrine auto-injectors to treat anaphylaxis. Research has been underway to develop non-needle epinephrine delivery systems—such as nasal sprays and sublingual films—with nasal spray now available in the U.S. and parts of the EU. With these innovations expanding internationally, we are actively advocating for equal access to all epinephrine delivery options in Canada.
Help inform our submission to the government in support of new epinephrine devices by sharing your experiences in managing food allergy and anaphylaxis. Take our short survey to provide your thoughts by August 8th, 2025.
Advocacy in action: Fall 2025 federal budget submission
Together with the Canadian Society of Allergy and Clinical Immunology (CSACI), we put forward our Fall 2025 pre-budget submission to request federal government support.
Within the submission, we focused on 7 core priorities:
- The need for recognition of food allergy as a serious medical condition
- Access to epinephrine and improving the treatment of anaphylaxis
- The importance of preventing food allergy
- Increasing access to diagnosis and treatments
- Addressing current allergen labelling gaps and gaps in foodservice
- Supporting Canada’s lower income households managing food allergy
- Having focused health research funding for food allergy
Check out the full details in our submission!
Advocacy in action: Championing the inclusion of students with food allergy in Canada’s National School Food Program
Following the federal government’s launch of the National School Food Program last year, Provinces across the country have chosen to participate.
As part of our ongoing advocacy to ensure students with food allergy can fully participate in the program, we are focusing our efforts on outreaching to each province as they enroll.
We have since met with the Ministry staff in Newfoundland & Labrador, Prince Edward Island, Nova Scotia, New Brunswick, Ontario, Alberta, British Columbia and Manitoba to offer our support to help educate school staff and foodservice providers on best practices for minimizing risks to students with food allergy.
You can count on us to ensure your voice is at the table. We’ll continue to follow the developments of this program as it rolls out and keep you updated on our discussions.
Advocacy in action: Making food allergy a priority with foodservice
As a part of our outreach to the foodservice industry, we published an article in the July/August issue of Foodservice and Hospitality Magazine: From ordering to delivery. This article focuses on best practices for allergen management in foodservice settings.
While we continue our long-term advocacy for standardized allergen management practices, we’re taking action now to make a difference to ensure food allergy is a priority with foodservice.
Learn more
From ordering to delivery: Best practices for allergen management in foodservice settings.
Think Food Allergy resources provide foodservice operators with the tools needed to create safer, more inclusive environments in their establishments.
Research: AllergyAware.ca e-learning training improves anaphylaxis preparedness in school staff
Recent research published in Allergy, Asthma & Clinical Immunology on AllergyAware.ca, our free online training program for educators and others, confirmed that this course is not only scalable and accessible, but that it improves confidence in anaphylaxis management among school staff.
“The AllergyAware e-learning course had significant benefits in equipping school personnel with essential knowledge and skills for managing anaphylaxis, offering a readily available and scalable training solution.”, as noted in the American Journal of Managed Care (AJMC).
Visit AllergyAware.ca and with back-to-school around the corner, let educators know about this award-winning, and evidenced-based free online course on the basics of food allergy and anaphylaxis.
Research: Aquestive Therapeutics provides international expansion update for Anaphylm™ (epinephrine) Sublingual Film for the treatment of anaphylaxis
There have been new developments in the emerging options for treating anaphylaxis for Canadians. Aquestive Therapeutics announced that Health Canada is meeting with them to discuss their planned New Drug Submission, Anaphylm™, an under-the-tongue epinephrine film.
If approved, this would be a new needle-free device option for treating anaphylaxis, giving Canadians a choice in the device that best meets their needs.
“These regulatory activities mark the pivotal first steps in Aquestive’s comprehensive ex-U.S. regulatory strategy,” said Dan Barber, President and Chief Executive Officer of Aquestive. “With our U.S. FDA New Drug Application recently accepted and a PDUFA target action date of January 31, 2026 established, we’re now positioned to pursue parallel regulatory pathways with the potential to bring needle-free, device-free Anaphylm to patients underserved by current treatment options. Our proven ability to successfully bring innovative therapies to market globally, combined with our oral epinephrine approach, positions us to fundamentally change how patients and caregivers manage severe allergic reactions, including anaphylaxis.”
As new treatments for anaphylaxis become available, we will continue to advocate powerfully and persistently to ensure Canadians have access to all forms of epinephrine delivery—because choice and accessibility matter.
Learn more
Check out Aquestive’s press release for more details on their international expansion update.
Take our short survey on epinephrine delivery devices to help inform our discussions with government.